Virtual Library

Start Your Search

Ioannis Stylianou

Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-12 - SWItch Maintenance PEmbrolizumab in Patients with Metastatic Non Small Cell Lung Cancer (SWIPE) (ID 14151)

      16:45 - 18:00  |  Author(s): Ioannis Stylianou

      • Abstract
      • Slides


      Pembrolizumab is currently indicated for first line use for patients with >50% PD-L1 overexpression and for pretreated patients with >1% PD-L1 expression with metastatic Non Small Cell Lung Cancer (NSCLC). There are currently no data for its use as maintenance treatment. SWIPE is a prospective single arm, one stage Phase II study offering Pembrolizumab as maintenance therapy to non-progressors after first line palliative chemotherapy with NSCLC. (NCT 02705820)

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Standard inclusion and exclusion criteria for checkpoint inhibitors studies apply, however also patients with WHO Performance Status (PS) 2 were allowed and there was no restriction on PD-L1 expression. Treatment consisted of Pembrolizumab 200 mg fixed dose every 3 weeks. Radiological assessement with CT scans every 9 weeks in the first year. The study employs a one stage phase II Fleming's design using Immune Related (IR) Progression Free Survival (PFS) at 1 year as primary endpoint. Using response hypotheses of H0 < 12 % and Ha> 25%, with a significance level α=0.05 and power 0.8, 48 patients are required to be entered into this study.

      4c3880bb027f159e801041b1021e88e8 Result

      Thirty-six (36) patients have been enrolled so far. 29 patients have more than 6 months follow up data, and are the subjects of this analysis. 23 males and 6 female patients. Median age 65 years (range 40-82). PS WHO 0 for 12 patients, WHO 1 for 15 patients and WHO 2 for 2 patients. Histology: adenocarcinoma in 22 patients and squamous in 7 patients. In terms of best radiological response 2 patients had a partial response and 13 patients stable disease. Median IR PFS is 6.8 months (CI 4.0-17.2). The 6 month and 1 year IR PFS rate is 60.7% and 45.8%. Median OS is 11.3 months (CI 7.4-15.2). The 6 month and 1 year OS rate is 65.5% and 48.0% (SPSS version 23). Toxicity was mainly grade 1-2; commonest being fatigue 18 patients (62%), anorexia, arthralgia and cough 10 patients (34%). One patient developed diabetes mellitus (grade 3) as auto-immune toxicity. Three (3) patients developed grade 3 dyspnoea, none of which were related to Pembrolizumab. There was one death during treatment due to sepsis, unlikely to be related to Pembrolizumab.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Maintenance Pembrolizumab is associated with a clinically meaningful disease control rate of almost 46% at 1 year with manageable toxicity.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.